Availability

The reports of the health effects studies listed below are now available through the U.S. Department of Commerce, National Technical Information Service (NTIS), 5285 Port Royal Road, Springfield, Virginia 22151, telephone 1–800–553–6847. There is a charge for these items as determined by NTIS.

Health effects study	NTIS document No.
Pancreatic Cancer Mortality and Residential Proximity to Railroad Refueling Facilities in Montana. ATSDR/HS–95/45	PB95–191359
Biologic Indicators of Exposure to Heavy Metals in Fish Consumers, American Samoa. ATSDR/HS–95/46	PB95–182994
Multisite Lead and Cadmium Exposure Study with Biological Markers Incorporated. ATSDR/HS–95/47	PB95–199188
Madison County Lead Exposure Study. ATSDR/HS–95/48	PB95–209631
Missouri Respiratory Study: Forest City and Glover, Missouri. ATSDR/HS–95/49	PB95–212742
Symptom and Illness Prevalence with Biomarkers Health Study for Calvert City and Southern Livingston County, Kentucky. ATSDR/HS–95/50.	PB95–222808
Analytic Study to Evaluate Associations Between Hazardous Waste Sites and Birth Defects. ATSDR/HS–95/51	PB95–199196
National Exposure Registry, Benzene Subregistry, Baseline Technical Report. ATSDR/HS–95/52	PB95–255766
Development and Evaluation of a Statewide Surveillance System: Hazardous Waste Sites and Cancer Incidence in New York State. ATSDR/HS–95/53.	PB95–230553
Biologic Indicators of Exposure to Cadmium and Lead: Palmerton, Pa. Part II. ATSDR/HS–95/54	PB95–225207
End-Stage Renal Disease Study, New York. ATSDR/HS–95/55	PB95–25389
A Case-Control Study to Determine Risk Factors for Elevated Blood Lead Levels in Children: Silver Valley, Idaho. ATSDR/HS–95/56.	PB95–253837

In accordance with 42 CFR 90.11, copies of these final reports have been distributed to the Environmental Protection Agency, the appropriate State and local government agencies, and the affected local communities.

ATSDR previously announced the availability of 44 final reports of health effect studies and a software package for the analysis of disease clusters (55 FR 31445, August 12, 1990; 57 FR 29091, June 30, 1992; 58 FR 29413, May 20, 1993; 58 FR 63378, December 1, 1993; 59 FR 47879, September 19, 1994; and 60 FR 25236, May 11, 1995). Additional final reports will be announced semiannually in the Federal Register as they become available.

Dated: October 19, 1995.

Claire V. Broome,

Deputy Administrator, Agency for Toxic Substances and Disease Registry.

[FR Doc. 95–26445 Filed 10–24–95; 8:45 am]

BILLING CODE 4163–70–P

Food and Drug Administration

[Docket No. 94F–0395]

Ecological Chemical Products Co.; Withdrawal of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 4B4432), filed by Ecological Chemical Products Co., proposing that the food additive regulations be amended to provide for the safe use of 2-hydroxy-propanoic acid homopolymer and (2-hydroxy-propanoic acid/caprolactone) block copolymer as components of adhesives intended to contact food.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3081.

SUPPLEMENTARY INFORMATION: In the Federal Register of November 23, 1994 (59 FR 60364), FDA published a notice that it had filed a petition (FAP 4B4432) on behalf of Ecological Chemical Products Co., 305 Water St., Newport, DE 19804. The petition proposed to amend the food additive regulations in § 175.105 *Adhesives* (21 CFR 175.105) to provide for the safe use of 2-hydroxy-propanoic acid homopolymer and (2-hydroxy-propanoic acid/caprolactone) block copolymer as a component of adhesives intended to contact food. Ecological Chemical Products Co. has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: October 10, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–26502 Filed 10–24–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95E–0260]

Determination of Regulatory Review Period for Purposes of Patent Extension; ULTRAVIST®

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for ULTRAVIST® and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health Affairs